X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs FRESENIUS KABI ONCO. - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA FRESENIUS KABI ONCO. ABBOTT INDIA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 39.1 22.1 176.8% View Chart
P/BV x 10.1 3.1 323.3% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ABBOTT INDIA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
FRESENIUS KABI ONCO.
Mar-13
ABBOTT INDIA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs6,110176 3,471.6%   
Low Rs3,99679 5,090.4%   
Sales per share (Unadj.) Rs1,552.237.7 4,118.9%  
Earnings per share (Unadj.) Rs188.85.1 3,707.0%  
Cash flow per share (Unadj.) Rs196.46.7 2,921.6%  
Dividends per share (Unadj.) Rs55.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs796.642.5 1,872.4%  
Shares outstanding (eoy) m21.25158.23 13.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.33.4 96.4%   
Avg P/E ratio x26.825.0 107.1%  
P/CF ratio (eoy) x25.718.9 135.9%  
Price / Book Value ratio x6.33.0 212.1%  
Dividend payout %29.10-   
Avg Mkt Cap Rs m107,37620,135 533.3%   
No. of employees `0003.31.2 288.4%   
Total wages/salary Rs m3,937703 559.9%   
Avg. sales/employee Rs Th9,929.35,176.2 191.8%   
Avg. wages/employee Rs Th1,185.1610.4 194.1%   
Avg. net profit/employee Rs Th1,207.7699.6 172.6%   
INCOME DATA
Net Sales Rs m32,9855,963 553.2%  
Other income Rs m1,17018 6,499.4%   
Total revenues Rs m34,1555,981 571.1%   
Gross profit Rs m5,2451,430 366.8%  
Depreciation Rs m162258 62.8%   
Interest Rs m38-26 -146.9%   
Profit before tax Rs m6,2151,216 511.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m2,203342 643.7%   
Profit after tax Rs m4,012806 497.8%  
Gross profit margin %15.924.0 66.3%  
Effective tax rate %35.428.1 126.0%   
Net profit margin %12.213.5 90.0%  
BALANCE SHEET DATA
Current assets Rs m22,6555,102 444.1%   
Current liabilities Rs m6,6812,385 280.1%   
Net working cap to sales %48.445.6 106.3%  
Current ratio x3.42.1 158.6%  
Inventory Days Days65150 43.2%  
Debtors Days Days29113 25.7%  
Net fixed assets Rs m8355,148 16.2%   
Share capital Rs m213158 134.3%   
"Free" reserves Rs m16,7156,556 255.0%   
Net worth Rs m16,9286,732 251.5%   
Long term debt Rs m0952 0.0%   
Total assets Rs m24,16210,388 232.6%  
Interest coverage x163.7-45.8 -357.6%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.40.6 237.8%   
Return on assets %16.87.5 223.3%  
Return on equity %23.712.0 198.0%  
Return on capital %36.914.6 253.0%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m3695,298 7.0%   
Fx outflow Rs m3,8071,772 214.8%   
Net fx Rs m-3,4383,525 -97.5%   
CASH FLOW
From Operations Rs m1,5271,274 119.8%  
From Investments Rs m-2,148-1,204 178.4%  
From Financial Activity Rs m-1,024-196 522.3%  
Net Cashflow Rs m-1,646-126 1,302.9%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 81.0 92.6%  
Indian inst/Mut Fund % 7.9 0.3 2,633.3%  
FIIs % 0.1 9.6 1.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 9.1 187.9%  
Shareholders   18,270 42,599 42.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   PLETHICO PHARMA  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  ELDER PHARMA  

Compare ABBOTT INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Weak; FMCG Stocks Drag(12:30 pm)

Stock markets in India are trading in negative territory weighed by fast-moving consumer goods (FMCG) stocks.

Related Views on News

BIOCON LTD at All Time High; BSE HEALTHCARE Index Up 0.6% (Market Updates)

Sep 26, 2018 | Updated on Sep 26, 2018

BIOCON LTD share price has hit an all time high at Rs 718 (up 0.4%). The BSE HEALTHCARE Index is up by 0.6%. Among the top gainers in the BSE HEALTHCARE Index today are BIOCON LTD (up 0.4%) and DR. REDDYS LAB (up 0.3%). The top losers include APOLLO HOSPITALS and SYNGENE INTERNATIONAL .

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Up 1.3% (Market Updates)

Sep 26, 2018 | Updated on Sep 26, 2018

DIVIS LABORATORIES share price has hit an all time high at Rs 1,409 (up 1.5%). The BSE HEALTHCARE Index is up by 1.3%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 1.5%) and ABBOTT INDIA (up 0.7%). The top losers include ALEMBIC PHARMA (down 0.1%) and ERIS LIFESCIENCES LIMITED (down 0.1%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 26, 2018 02:13 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - PANACEA BIOTECH COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS